p53 pathway dysfunction in primary childhood ependymomas

Pediatric Blood and Cancer

Volumn 46, Issue 5, 2006, Pages 604-613

  Gaspar, Nathalie ^a   Grill, Jacques ^a,b   Geoerger, Birgit ^a   Lellouch Tubiana, Arielle ^c   Michalowski, Mariana Bohns ^d   Vassal, Gilles ^a  

^a INSTITUT GUSTAVE ROUSSY   (France)

^b CNRS   (France)

^c HÔPITAL NECKER ENFANTS MALADES   (France)

^d CHU La Tronche and University   (France)

Author keywords

Ependymoma; MDM2; p14ARF; p53 pathway; PAX5; Xenograft models

Indexed keywords

PROTEIN MDM2; PROTEIN P14ARF; PROTEIN P53; TRANSCRIPTION FACTOR PAX5;

APOPTOSIS; ARTICLE; CELL DEATH; CHILD; CHILDHOOD CANCER; CLINICAL ARTICLE; DNA DAMAGE; EPENDYMOMA; FEMALE; FLOW CYTOMETRY; HUMAN; IMMUNOHISTOCHEMISTRY; INFANT; MALE; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN FUNCTION; RADIOSENSITIVITY; RELAPSE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR GROWTH; TUMOR SUPPRESSOR GENE; TUMOR XENOGRAFT; WESTERN BLOTTING;

ANIMALS; B-CELL-SPECIFIC ACTIVATOR PROTEIN; BLOTTING, WESTERN; CHILD; CHILD, PRESCHOOL; DNA METHYLATION; EPENDYMOMA; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INFANT; MALE; MICE; PROMOTER REGIONS (GENETICS); PROTO-ONCOGENE PROTEINS C-MDM2; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; TRANSPLANTATION, HETEROLOGOUS; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEIN P14ARF; TUMOR SUPPRESSOR PROTEIN P53;

EID: 33645302619     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.20532     Document Type: Article

References (41)

1. Grill J, Pascal C, Chantal K. Childhood ependymoma: A systematic review of treatment options and strategies. Paediatr Drugs 2003;5:533-543.
2. Bouffet E, Perilongo G, Canete A, et al. Intracranial ependymomas in children: A critical review of prognostic factors and a plea for cooperation. Med Pediatr Oncol 1998;30:319-329; discussion 329-331.
3. Zamecnik J, Snuderl M, Eckschlager T, et al. Pediatric intracranial ependymomas: Prognostic relevance of histological, immunohistochemical, and flow cytometric factors. Mod Pathol 2003;16:980-991.
4. Merchant TE, Mulhern RK, Krasin MJ, et al. Preliminary results from a phase ii trial of conformal radiation therapy and evaluation of radiation-related CNS effects for pediatric patients with localized ependymoma. J Clin Oncol 2004;22:3156-3162.
5. Lowe SW, Ruley HE, Jacks T, et al. P53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell 1993;74:957-967.
6. Agirre X, Vizmanos JL, Calasanz MJ, et al. Methylation of CpG dinucleotides and/or CCWGG motifs at the promoter of TP53 correlates with decreased gene expression in a subset of acute lymphoblastic leukemia patients. Oncogene 2003;22:1070-1072.
7. Stuart ET, Haffner R, Oren M, et al. Loss of p53 function through PAX-mediated transcriptional repression. EMBO J 1995;14:5638-5645.
8. Kleihues P, Louis DN, Scheithauer BW, et al. The who classification of tumors of the nervous system. J Neuropathol Exp Neurol 2002;61:215-225; discussion 226-219.
9. Workman P, Twentyman P, Balkwill F, et al. United Kingdom Coordinating Committee on Cancer Research (UKCCCR) Guidelines for the welfare of animals in experimental neoplasia (second edition). Br J Cancer 1998;77:1-10.
10. Vassal G, Terrier-Lacombe MJ, Lellouch-Tubiana A, et al. Tumorigenicity of cerebellar primitive neuro-ectodermal tumors in athymic mice correlates with poor prognosis in children. Int J Cancer 1996;69:146-151.
11. Flaman JM, Frebourg T, Moreau V, et al. A simple p53 functional assay for screening cell lines, blood, and tumors. Proc Natl Acad Sci USA 1995;92:3963-3967.
12. Geoerger B, Grill J, Opolon P, et al. Oncolytic activity of the E1B-55 kDa-deleted adenovirus Onyx-015 is independent of cellular p53 status in human malignant glioma xenografts. Cancer Res 2002;62:764-772.
13. Geoerger B, Grill J, Opolon P, et al. Potentiation of radiation therapy by the oncolytic adenovirus d11520 (Onyx-015) in human malignant glioma xenografts. Br J Cancer 2003;89:577-584.
14. Herman JG, Graff JR, Myohanen S, et al. Methylation-specific PCR: A novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci USA 1996;93:9821-9826.
15. Zochbauer-Muller S, Fong KM, Virmani AK, et al. Aberrant promoter methylation of multiple genes in non-small cell lung cancers. Cancer Res 2001;61:249-255.
16. Kozmik Z, Sure U, Ruedi D, et al. Deregulated expression of PAX5 in medulloblastoma. Proc Natl Acad Sci USA 1995;92:5709-5713.
17. Grill J, Avet-Loiseau H, Lellouch-Tubiana A, et al. Comparative genomic hybridization detects specific cytogenetic abnormalities in pediatric ependymomas and choroid plexus papillomas. Cancer Genet Cytogenet 2002;136:121-125.
18. Ohgaki H, Eibl RH, Schwab M, et al. Mutations of the p53 tumor suppressor gene in neoplasms of the human nervous system. Mol Carcinog 1993;8:74-80.
19. Fink KL, Rushing EJ, Schold SC Jr., et al. Infrequency of p53 gene mutations in ependymomas. J Neurooncol 1996;27:111-115.
20. Nozaki M, Tada M, Matsumoto R, et al. Rare occurrence of inactivating p53 gene mutations in primary non-astrocytic tumors of the central nervous system: Reappraisal by yeast functional assay. Acta Neuropathol (Berl) 1998;95:291-296.
21. Alonso ME, Bello MJ, Gonzalez-Gomez P, et al. Aberrant promoter methylation of multiple genes in oligodendrogliomas and ependymomas. Cancer Genet Cytogenet 2003;144:134-142.
22. Tong CY, Ng HK, Pang JC, et al. Molecular genetic analysis of non-astrocytic gliomas. Histopathology 1999;34:331-341.
23. Suzuki Soiwaki T. Amplification and overexpression of mdm2 gene in ependymomas. Mod Pathol 2000;13:548-553.
24. Kramer DL, Parmiter AH, Rorke LB, et al. Molecular cytogenetic studies of pediatric ependymomas. J Neurooncol 1998;37:25-33.
25. Reardon DA, Entrekin RE, Sublett J, et al. Chromosome arm 6q loss is the most common recurrent autosomal alteration detected in primary pediatric ependymoma. Genes Chromosomes Cancer 1999;24:230-237.
26. Carter M, Nicholson J, Ross F, et al. Genetic abnormalities detected in ependymomas by comparative genomic hybridisation. Br J Cancer 2002;86:929-939.
27. Jeuken JW, Sprenger SH, Wesseling P. Comparative genomic hybridization: Practical guidelines. Diagn Mol Pathol 2002;11:193-203.
28. Dyer S, Prebble E, Davison V, et al. Genomic imbalances in pediatrie intracranial ependymomas define clinically relevant groups. Am J Pathol 2002;161:2133-2141.
29. Korshunov A, Golanov A, Timirgaz V. P14ARF protein (fl-132) immunoreactivity in intracranial ependymomas and its prognostic significance: An analysis of 103 cases. Acta Neuropathol (Berl) 2001;102:271-277.
30. Rousseau E, Ruchoux MM, Scaravilli F, et al. CDKN2A, CDKN2B and p14ARF are frequently and differentially methylated in ependymal tumours. Neuropathol Appl Neurobiol 2003;29:574-583.
31. Stuart ET, Kioussi C, Aguzzi A, et al. Pax5 expression correlates with increasing malignancy in human astrocytomas. Clin Cancer Res 1995;1:207-214.
32. Mihara Y. Establishment and characterization of 5 cell lines derived from human grain tumors. Kumamoto Med J 1986;39:25-41.
33. Brisson C, Lelong-Rebel I, Mottolese C, et al. Establishment of human tumoral ependymal cell lines and co-culture with tubular-like human endothelial cells. Int J Oncol 2002;21:775-785.
34. McLendon RE, Fung KM, Bentley RC, et al. Production and characterization of two ependymoma xenografts. J Neuropathol Exp Neurol 1996;55:540-548.
35. Takahashi T, Mitsuhashi N, Furuta M, et al. Apoptosis induced by heavy ion (carbon) irradiation of two human tumours with different radiosensitivities in vivo: Relative biological effectiveness (RBE) of carbon beam. Anticancer Res 1998;18:253-256.
36. Horowitz ME, Parham DM, Douglass EC, et al. Development and characterization of human ependymoma xenograft hxbr5. Cancer Res 1987;47:499-504.
37. Vassal G, Boland I, Santos A, et al. Potent therapeutic activity of irinotecan (CPT-11) and its schedule dependency in medulloblastoma xenografts in nude mice. Int J Cancer 1997;73:156-163.
38. Mattern J, Bak M, Hahn EW, et al. Human tumor xenografts as model for drug testing. Cancer Metastasis Rev 1988;7:263-284.
39. Neely JE, Ballard ET, Britt AL, et al. Characteristics of 85 pediatric tumors heterotransplanted into nude mice. Exp Cell Biol 1983;51:217-227.
40. Castellano-Sanchez AA, Schemankewitz E, Mazewski C, et al. Pediatric chordoid glioma with chondroid metaplasia. Pediatr Dev Pathol 2001;4:564-567.
41. Hamilton RL, Pollack IF. The molecular biology of ependymomas. Brain Pathol 1997;7:807-822.